TrialNeuro-oncology2020

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).

Carmen Balana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.